Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Japan Approves Verquvo, Evrysdi, 2 CGRP Migraine Meds and More
Japan on June 23 granted approval to a throng of new medicines including Bayer Yakuhin’s heart failure drug Verquvo (vericiguat) and the first oral treatment for spinal muscular atrophy (SMA), Evrysdi (risdiplam), by Chugai Pharmaceutical. The Ministry of Health, Labor…
To read the full story
Related Article
- Heart Failure Med Verquvo Makes Japan Debut: Bayer
September 16, 2021
- Eisai Rolls Out Tazverik for EZH2-Positive Follicular Lymphoma
August 17, 2021
- August Listing OK’ed for Evrysdi, Veklury, Verquvo, 2 CGRP Migraine Meds and More
August 4, 2021
- Eisai’s EZH2 Inhibitor, 3 More New Drugs Clear Key Panel, June OK Likely
May 31, 2021
- Japan Panel Clears 1st Oral SMA Drug, 2 Migraine Meds, RNAi Therapy and More
May 27, 2021
- Bayer’s Heart Failure Med Now in Line for June Approval
April 30, 2021
REGULATORY
- Zepbound’s OSA Indication Up for Panel Review on April 24
April 20, 2026
- Japan Sees No Need to Prioritize Naphtha Supply for Medical Use, METI Says
April 20, 2026
- Minister Noncommittal on Drug Price Measures amid Middle East Crisis
April 20, 2026
- LDP Pharma Project Team to Compile Roadmap Proposals after Industry Hearings
April 17, 2026
- DPJ Leader to Urge Drug Price Hikes, “Freeze” on Off-Year Revisions
April 17, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…